Shopping Cart 0
Cart Subtotal
USD 0

Addex Therapeutics Ltd (ADXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Addex Therapeutics Ltd (Addex) develops orally available, small molecule allosteric modulators for neurological disorders. The company's product pipeline consists of its lead products, dipraglurant (mGluR5 negative allosteric modulator or NAM) to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGluR2 positive allosteric modulator or PAM) for the treatment of epilepsy. It also conducts clinical and preclinical development of drug candidates for indications such as addiction, Charcot-Marie-Tooth Type 1a (CMT1A) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder, autism and other disorders, Parkinson's disease, anxiety, resistant depression, cognitive deficits and psychosomatic disorders. Addex is headquartered in Plan-les-Ouates, Geneva, Switzerland.

Addex Therapeutics Ltd (ADXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

New Enterprise Associates and New Leaf Venture Partners Invest USD43 Million in Addex Therapeutics 10

Partnerships 12

Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 12

Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 13

Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 14

Addex Therapeutics Plans To Enter Into Co-Development Agreement For Dipraglurant 15

Licensing Agreements 16

Indivior Enters into Licensing Agreement with Addex Pharma 16

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 17

Equity Offering 18

Addex Therapeutics Raises USD3 Million in Private Placement of Shares 18

Addex Therapeutics Raises Funds through Private Placement of Shares 19

Addex Therapeutics Raises USD2.8 Million in Private Placement of Shares 20

Addex Therapeutics Completes Private Placement Of Shares For USD 3.5 Million 21

Addex Therapeutics Completes Private Placement Of Shares For USD 11 Million 23

Addex Therapeutics Ltd-Key Competitors 24

Addex Therapeutics Ltd-Key Employees 25

Addex Therapeutics Ltd-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Sep 28, 2018: Addex reports 2018 half-year financial results and provides corporate update 27

Apr 30, 2018: Addex Announces 2017 Full Year Results 28

Sep 26, 2017: Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results 30

Apr 05, 2017: Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results 31

Corporate Communications 32

Feb 07, 2018: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management 32

Sep 18, 2017: Addex Makes Changes to Executive Management Team 33

Product News 34

01/31/2017: Addex Awarded USD 835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease 34

Other Significant Developments 35

Mar 20, 2018: Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association 35

Mar 19, 2018: Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Addex Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

New Enterprise Associates and New Leaf Venture Partners Invest USD43 Million in Addex Therapeutics 10

Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 12

Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 13

Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 14

Addex Therapeutics Plans To Enter Into Co-Development Agreement For Dipraglurant 15

Indivior Enters into Licensing Agreement with Addex Pharma 16

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 17

Addex Therapeutics Raises USD3 Million in Private Placement of Shares 18

Addex Therapeutics Raises Funds through Private Placement of Shares 19

Addex Therapeutics Raises USD2.8 Million in Private Placement of Shares 20

Addex Therapeutics Completes Private Placement Of Shares For USD 3.5 Million 21

Addex Therapeutics Completes Private Placement Of Shares For USD 11 Million 23

Addex Therapeutics Ltd, Key Competitors 24

Addex Therapeutics Ltd, Key Employees 25

Addex Therapeutics Ltd, Other Locations 26

Addex Therapeutics Ltd, Subsidiaries 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Addex Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Addex Therapeutics Ltd (Addex) develops orally available, small molecule allosteric modulators for neurological disorders. The company's product pipeline consists of its lead products, dipraglurant (mGluR5 negative allosteric modulator or NAM) to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGluR2 positive allosteric modulator or PAM) for the treatment of epilepsy. It also conducts clinical and preclinical development of drug candidates for indications such as addiction, Charcot-Marie-Tooth Type 1a (CMT1A) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder, autism and other disorders, Parkinson's disease, anxiety, resistant depression, cognitive deficits and psychosomatic disorders. Addex is headquartered in Plan-les-Ouates, Geneva, Switzerland.

Addex Therapeutics Ltd (ADXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

New Enterprise Associates and New Leaf Venture Partners Invest USD43 Million in Addex Therapeutics 10

Partnerships 12

Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 12

Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 13

Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 14

Addex Therapeutics Plans To Enter Into Co-Development Agreement For Dipraglurant 15

Licensing Agreements 16

Indivior Enters into Licensing Agreement with Addex Pharma 16

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 17

Equity Offering 18

Addex Therapeutics Raises USD3 Million in Private Placement of Shares 18

Addex Therapeutics Raises Funds through Private Placement of Shares 19

Addex Therapeutics Raises USD2.8 Million in Private Placement of Shares 20

Addex Therapeutics Completes Private Placement Of Shares For USD 3.5 Million 21

Addex Therapeutics Completes Private Placement Of Shares For USD 11 Million 23

Addex Therapeutics Ltd-Key Competitors 24

Addex Therapeutics Ltd-Key Employees 25

Addex Therapeutics Ltd-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Sep 28, 2018: Addex reports 2018 half-year financial results and provides corporate update 27

Apr 30, 2018: Addex Announces 2017 Full Year Results 28

Sep 26, 2017: Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results 30

Apr 05, 2017: Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results 31

Corporate Communications 32

Feb 07, 2018: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management 32

Sep 18, 2017: Addex Makes Changes to Executive Management Team 33

Product News 34

01/31/2017: Addex Awarded USD 835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease 34

Other Significant Developments 35

Mar 20, 2018: Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association 35

Mar 19, 2018: Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Addex Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

New Enterprise Associates and New Leaf Venture Partners Invest USD43 Million in Addex Therapeutics 10

Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 12

Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 13

Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 14

Addex Therapeutics Plans To Enter Into Co-Development Agreement For Dipraglurant 15

Indivior Enters into Licensing Agreement with Addex Pharma 16

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 17

Addex Therapeutics Raises USD3 Million in Private Placement of Shares 18

Addex Therapeutics Raises Funds through Private Placement of Shares 19

Addex Therapeutics Raises USD2.8 Million in Private Placement of Shares 20

Addex Therapeutics Completes Private Placement Of Shares For USD 3.5 Million 21

Addex Therapeutics Completes Private Placement Of Shares For USD 11 Million 23

Addex Therapeutics Ltd, Key Competitors 24

Addex Therapeutics Ltd, Key Employees 25

Addex Therapeutics Ltd, Other Locations 26

Addex Therapeutics Ltd, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Addex Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.